Asset profile
cyclosporine
Unknown / undisclosed
Evidence outlook
Approved: Dry Eye Disease
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Competitive landscape
5 competitors in this universe: 0 direct rivals (same mechanism and indication), 3 same-class, 2 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Cyclosporine: this drug | Approved | — | Calcineurin | ||
| Voclosporin (Lupkynis) | Approved | Small molecule | Calcineurin, Cyclophilin A (leading to calcineurin inhibition) | ||
| Extended-Release Tacrolimus (VI-0106) | Phase 3 | Small molecule | Calcineurin | ||
| Nanosomal Tacrolimus | Phase 2 | Small molecule | Calcineurin | ||
| PL9643 | Phase 3 | Peptide | — | ||
| Reproxalap | Phase 3 | Small molecule | — |
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(17 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (2)
2027 (8)
February 2027 (2)
What to watch
What to watch
April 2027 (1)
What to watch
August 2027 (2)
What to watch
What to watch
November 2027 (1)
What to watch
December 2027 (2)
What to watch
What to watch
2028 (2)
2029 (2)
June 2029 (1)
What to watch
December 2029 (1)
What to watch
2030 (2)
April 2030 (1)
What to watch
June 2030 (1)
What to watch
2031 (1)
October 2031 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.